We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Carecapital | CARE | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.815 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.815 | 0.815 |
| Top Posts |
|---|
Posted at 06/9/2012 15:05 by praipus Hi Fen, yep excellent move helps demistify the opportunity. Three clear chances of success rather than one:-). Demographics, and costs associated with cancer care can only be reduced with high tec prevention and or cheaper more effective treatment. CARE could win which ever way the future goes.Very good news IMHO. P. |
Posted at 28/6/2012 07:25 by mike_f Appointment of Non-executive DirectorCareCapital (AIM: CARE) is pleased to announce the appointment of Trevor Brown as a Non-executive Director with immediate effect. Trevor Brown (66) has been a strategic investor in real estate and equities for more than 30 years. Mr Brown is a director of Free Association Books Limited in London. He has a beneficial interest as at the date of this announcement in 15,334,001 ordinary shares of CareCapital, representing 9.38% of the Company's current issued share capital. There is no further information required to be disclosed in relation to Rule 17 and Schedule 2 (g) of the AIM Rules for Companies. Commenting on the appointment, Dr Mike Sinclair, CareCapital's CEO, said, "I am pleased that Trevor has agreed to join the Board as a Non-executive Director. He is, and has been, a supporter of our plans to refocus CareCapital on the provision of advanced cancer treatment services. His experience and track record will greatly benefit our Board, our management team and our shareholders. I welcome him to CareCapital." |
Posted at 12/6/2012 07:52 by 27howard Agreement with Varigen TechnologiesShare this article Alert TIDMCARE RNS Number : 1427F Carecapital Group plc 12 June 2012 12 June 2012 CARECAPITAL GROUP PLC ("CareCapital" or "the Company") Agreement with Varigen Technologies Diagnosis and Treatment of Malignant Diseases Based on Genetic Testing, Initially Targeted at Women's Health Care CareCapital (AIM: CARE) announces that it has signed a mutually exclusive agreement ("the Agreement") with Varigen Technologies ("Varigen") to use Varigen's expertise in the areas of genetic testing and its application to both the diagnosis and development of personalized medical treatments for patients with malignant diseases. Under the Agreement, the specialist services supplied by Varigen will initially be made available at CareCapital's planned medical centre in Folkestone, dedicated exclusively to women's health. Varigen will be entitled to a share, after deduction of all operating costs, of 30% of revenues derived from the provision of the services, with CareCapital retaining the remainder. Varigen is a company established by Mark Hoser, an expert in the field of genetic and medical diagnostics. Following the award of a PhD from St Thomas' Hospital in haematology and coagulation diagnostics, Mark subsequently held various management positions with large, international pharmaceutical companies before founding GeneForm Technologies in 2003 to exploit his patents in molecular diagnostics and pharmacogenomics. After a successful trade sale of GeneForm Technologies, he has continued his focus on personalized medicine and rapid, next generation diagnostics as well as genotyping technologies for the prediction of drug efficiency in oncology. Commenting on the Agreement, Mike Sinclair, CareCapital's CEO, said,"The addition of Mark's expertise via this agreement with Varigen Technologies is exactly on strategy for us as we build and grow our specialist cancer services business. The services developed with Varigen will be first available at our dedicated women's health care facility but can then be rolled out more widely." Mark Hoser of Varigen, added, "The personalisation of diagnosis and treatment are critical steps in the future of medical care and translate to best care and improved quality of life for the patient. Varigen is excited to contribute to CareCapital's endeavour's in making this a reality." For further information, please visit www.carecapital.co.u |
Posted at 08/6/2012 15:48 by 27howard I've updated the header, how good is that appointment today, the market totallyignores this tiny market cap. Karen Bullivant to join cancer treatment services team CareCapital (AIM: CARE) is pleased to announce the appointment of Ms Karen Bullivant as Director of Marketing and Business Development effective full time from 1 January 2013, but part time with immediate effect. A non-Board appointment, Karen joins the team at CareCapital responsible for developing and growing the Company's cancer treatment services business. Karen's career in strategic marketing, branding and new business development in healthcare has included working in the United States, the Middle East and Europe. She worked for Pfizer in the USA before moving to London in 2001. In the UK, she initially worked for the specialist healthcare division of Young & Rubicam before moving to Bupa where she focused on creating customised marketing solutions that achieved commercial results while retaining goals that were centred on customer and patient needs. In 2005, Karen joined The London Clinic as Marketing Director where she most recently launched its GBP90 million cancer centre with an integrated B2C and B2B campaign. Karen holds a BA in Philosophy and an MBA in Marketing. Karen has been a Trustee of the University College London Cancer Trust since 2010 and has most recently focused, in this pro bono role, on fundraising for translational research which will create targeted and patient-tailored therapies. These new advances will someday enable clinicians to stratify patients based on the genetic profile of their individual tumours and to predict what treatment combinations will give the best patient outcome with the lowest side effects. |
Posted at 08/6/2012 13:24 by 27howard Thanks for that Hatetrader and welcome to Care.Check this out, he had a lot more in January so looks like he is buying them back cheaper. Holding in Company Share this article Alert TIDMCARE RNS Number : 6465V Carecapital Group plc 16 January 2012 16 January 2012 CARECAPITAL GROUP PLC ("CareCapital" or "the Company") Holding in Company CareCapital Plc (AIM: CARE), the healthcare real estate developer and owner, was notified on 16 January 2012 by Mr Trevor Brown that, following a purchase of shares on 16 January 2012, he has a beneficial interest in 21,545,668 ordinary shares in CareCapital, which represents 28.07% of the Company's current issued share capital. |
Posted at 08/6/2012 13:12 by scburbs So who was the seller then? Trevor Brown has certainly been active on this one. Presumably this series of trades has materially brought down his average."CareCapital Plc (AIM: CARE), the healthcare real estate developer and owner, was notified on 16 January 2012 by Mr Trevor Brown that, following a purchase of shares on 16 January 2012, he has a beneficial interest in 21,545,668 ordinary shares in CareCapital, which represents 28.07% of the Company's current issued share capital." "CareCapital (AIM: CARE), the healthcare real estate developer and owner, was notified on 02 May 2012 by Mr Trevor Brown that, following disposal of shares, he has a beneficial interest in 9,100,668 ordinary shares in CareCapital, which represents 6.1% of the Company's current issued share capital." "CareCapital (AIM: CARE), the healthcare real estate developer and owner, was notified on 7 June 2012 by Mr Trevor Brown that, following the acquisition of 5,000,000 ordinary shares in CareCapital, he has a beneficial interest in 14,100,668 ordinary shares, which represents 8.6% of the Company's current issued share capital." |
Posted at 02/5/2012 21:54 by 27howard Carecapital Group plc19 April 2012 19 April 2012 CARECAPITAL GROUP PLC ("CareCapital" or "the Company" New Division to Focus on Women's Health First Project Launched in Folkestone CareCapital announces the formation of a new division to focus on the development of dedicated medical centres focused exclusively on women's health. The first project will be based at the Company's Folkestone property. The property, which is currently developed as a cosmetic dental surgery, will undergo an internal makeover to provide consulting rooms, a laboratory, luxurious waiting and resting areas and general administration space. This will enable specialists in fields associated with women's health such as gynaecology, dermatology, breast care and nutrition to promote a holistic approach to healthcare in a private, attractive setting. The inclusion of an onsite laboratory will mean pathology work can be processed quickly and results given during the patient's visit. CareCapital, through its 75% owned subsidiary Oncotherapy Resources Limited, will be investigating the feasibility of offering the Xoft System(R) at the facility. The Xoft System uses an electronic X-ray source instead of a radioactive isotope to deliver radiation internally. The low energy and rapid dose fall-off of the electronic source allow for treatment in rooms with reduced shielding requirements compared to conventional radiation therapy. It is lightweight and mobile and can be moved easily between treatment locations. This means that it can overcome the logistical challenges faced by many patients who may have to travel long distances to access conventional radiotherapy. The 8,500 sq ft Folkestone facility is spread over five floors with a substantial lobby/reception area and four floors of consultation and administration space. It is anticipated that given the strength of the professionals and the environment created within the facility that this will become a "destination" health centre with visitors travelling from London and France. Work on the new facility is currently underway with an estimated opening date of early 2013 |
Posted at 28/3/2012 07:08 by sharewinner2 CARECAPITAL GROUP PLC("CareCapital", "the Group" or "the Company") Restructuring, Proposed Change of Name Changes to Senior Management and Board Responsibilities Care Capital announces a restructuring to reflect its strategy to reposition the Group primarily as an investor in, and provider of, advanced cancer treatments. Current investments in medical centre development projects are to be transferred to the Group's wholly owned subsidiary - The Healthcare Property Company Limited - which will continue to progress existing schemes and expand through securing new medical centre projects in the UK. This company will also provide property related support services to the wider Group. The Company also announces that it will be seeking shareholder authority at the earliest opportunity to change its name to Advanced Oncotherapy plc. Changes to Board and senior management responsibilities, all with immediate effect, to reflect the shift in strategic focus are set out below: · Lord Evans of Watford, currently the Senior Independent Non-executive Director, has become Non-executive Chairman · Dr Michael Sinclair has stepped down as Executive Chairman to become Group Chief Executive with a focus on developing and growing the Group's interests in advanced cancer treatments · Paul Stacey, currently Chief Executive, has become Managing Director of The Healthcare Property Company Limited · Dr Sinclair and Mr Stacey will continue as Directors of the Company. Further appointments to the Board are expected to be announced in due course. Commenting on the restructuring, proposed name change and new team responsibilities, Mike Sinclair, Group Chief Executive, said, "The new direction for the Company is today recognised in the restructuring of our businesses and management responsibilities as well as the proposed change of name and sector re-classification. I very much hope that this sharper focus will enable the management team to continue to restore and create value for shareholders through our historic real estate activities and our newer, higher potential cancer treatment interests." |
Posted at 14/2/2012 07:50 by 27howard Jenny today will be a blockbuster.CareCapital (AIM: CARE) is pleased to announce the completion of The Warrens Medical Centre in Thingwell, Wirral. The building has a gross internal floor area of 2,028 sq m with 98 parking spaces and is valued at some £5 million. It houses The West Wirral Group Practice, Wirral NHS Community Trust and a pharmacy. The centre was forward sold in November 2010 to MedicX Fund Limited, the specialist primary care infrastructure investor. CareCapital was appointed preferred developer in early 2008 following a competitive tender advertised in the Official Journal of the European Union. A protracted planning process saw permission granted in October 2009 with construction commencing in December 2010 and completing in January 2012. The Warrens Medical Centre formed part of the Company's medical centre development pipeline which now comprises a medical centre, pharmacy and related ancillary areas in Allesley, Coventry; a medical centre in Bishops Stortford, where construction will commence this year, and four medical centres in Wales that are part of CareCapital's joint-venture with Gaufron Healthcare, of which Buckley and Swansea will also see construction commence this year. It is intended that the majority of these projects will be subject to forward funding and sale arrangements. In addition, as reported in the Trading Update announced on 31 January 2012, the Group continues to investigate additional innovative, but proven, cancer treatments in addition to its 28.75% shareholding in Advanced Proton Solutions (Holdings) Ltd - the company that is pioneering the use of Proton Beam Therapy in the UK and which has secured planning approval for its first London based centre off Moorgate in the City of London, within easy access of a number of London's major hospitals. |
Posted at 04/2/2012 09:42 by 27howard Karen Bullivant to join cancer treatment services teamCareCapital (AIM: CARE) is pleased to announce the appointment of Ms Karen Bullivant as Director of Marketing and Business Development effective full time from 1 January 2013, but part time with immediate effect. A non-Board appointment, Karen joins the team at CareCapital responsible for developing and growing the Company's cancer treatment services business. Karen's career in strategic marketing, branding and new business development in healthcare has included working in the United States, the Middle East and Europe. She worked for Pfizer in the USA before moving to London in 2001. In the UK, she initially worked for the specialist healthcare division of Young & Rubicam before moving to Bupa where she focused on creating customised marketing solutions that achieved commercial results while retaining goals that were centred on customer and patient needs. In 2005, Karen joined The London Clinic as Marketing Director where she most recently launched its GBP90 million cancer centre with an integrated B2C and B2B campaign. Karen holds a BA in Philosophy and an MBA in Marketing. Karen has been a Trustee of the University College London Cancer Trust since 2010 and has most recently focused, in this pro bono role, on fundraising for translational research which will create targeted and patient-tailored therapies. These new advances will someday enable clinicians to stratify patients based on the genetic profile of their individual tumours and to predict what treatment combinations will give the best patient outcome with the lowest side effects. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
